A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-De-escalation Study of LMN-101in Healthy Volunteers Challenged With Campylobacter Jejuni
Latest Information Update: 21 Nov 2022
At a glance
- Drugs LMN 101 (Primary) ; Azithromycin; Ciprofloxacin
- Indications Campylobacter infections
- Focus Adverse reactions
- Sponsors Lumen Bioscience
Most Recent Events
- 15 Nov 2022 Status changed from active, no longer recruiting to completed.
- 29 Mar 2022 Planned primary completion date changed from 1 May 2022 to 1 Sep 2022.
- 29 Mar 2022 Status changed from recruiting to active, no longer recruiting.